An EGFR‐targeting antibody–drug conjugate LR004‐VC‐MMAE: potential in esophageal squamous cell carcinoma and other malignancies

An EGFR‐targeting antibody–drug conjugate LR004‐VC‐MMAE: potential in esophageal squamous cell carcinoma and other malignancies

Epidermal growth factor receptor (EGFR) is a rational target for cancer therapy, because its overexpression plays an important oncogenic role in a variety of solid tumors; however, EGFR‐targeted antibody–drug conjugate (ADC) therapy for esophageal squamous cell carcinoma (ESCC) is exceedingly rare....

Full description

Bibliographic Details
Main Authors: Xin‐yue Hu, Rong Wang, Jie Jin, Xiu‐jun Liu, A‐long Cui, Lian‐qi Sun, Yan‐ping Li, Yi Li, Yu‐cheng Wang, Yong‐su Zhen, Qing‐fang Miao, Zhuo‐rong Li
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Molecular Oncology
Subjects:
antitumor activity
EGFR
ESCC
LR004
LR004‐VC‐MMAE
preparation
Online Access:https://doi.org/10.1002/1878-0261.12400

Internet

https://doi.org/10.1002/1878-0261.12400

Similar Items